Announcements Trials
Browse Landscape

Phase

Phase 2 54Phase 3 22Phase NA 4Phase 2/3 4Phase 1 3Phase 1/2 2Phase 4 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER_GOV 2OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Waldenstrom Macroglobulinemia 1Neoplasms 1Metastatic HER2 Positive Gastroesophageal Junction Cancer 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × XELOX × Clear all
NCT06650332 2024-10-21

Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients

Zhejiang Cancer Hospital

Phase 1/2 Recruiting
90 enrolled
Gastrointestinal

Metastatic HER2 Positive Gastroesophageal Junction Cancer

NCT04522284 2023-03-29

PRECISE CURATE.AI Pilot Clinical Trial

National University Hospital, Singapore

Phase 1/2 Unknown
20 enrolled
Lymphoid

Waldenstrom Macroglobulinemia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡